Clinical trials
Metabolic Dysfunction-Associated Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated liver disease clinical trials, each written for real people, not researchers. We’re tracking 112 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06739330Recruiting
Thyroid function and fatty liver disease study
This study looks at how your thyroid might be linked to fatty liver disease (MAFLD). It aims to help researchers understand if thyroid problems play a role in this condition, which could lead to better treatments.
Tanta, El-GharbiaAges 18 years+ - NCT07534241Recruiting
Reishi Mushroom for Fatty Liver Disease
This study tests whether reishi mushroom (a type of fungus) can improve liver health in people with metabolic dysfunction-associated fatty liver disease—a condition where fat builds up in the liver. Researchers want to see if this natural supplement can reduce liver inflammation and improve blood sugar and cholesterol levels.
LahoreAges 35–65 - NCT07527910RecruitingPhase 2
Study of ALN-PNP with or without tirzepatide for fatty liver disease
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Tucson, ArizonaAges 18–75 - NCT07518784Recruiting
Testing a new liver scanning device for fatty liver disease
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
La Jolla, CaliforniaAges 18 years+ - NCT07491458RecruitingPhase 2
Study of HU6 versus placebo for adults with MASH
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Chandler, ArizonaAges 30 years+ - NCT07476703Recruiting
Extended study on the SCAPIS Stockholm reexamined group
This trial studies data and samples from people already taking part in the main SCAPIS reexamination study in Stockholm. It looks for new findings to help understand heart and lung health.
StockholmAges 56–74 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07456332Enrolling by invitation
Digital lifestyle program for weight loss with HIV and fatty liver
This trial tests a digital lifestyle program (diet and activity coaching) to help people with HIV and fatty liver disease lose weight. It aims to see if the program can reduce body fat in the liver and improve overall health.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT06386094Recruiting
Fatty Liver Disease and Heart Function Study
This study checks how fatty liver disease (a condition where fat builds up in the liver) affects the heart. If you have this liver condition and are between 18 and 65, you may help doctors understand the link between liver health and heart function.
Chandigarh, ChandigarhAges 18–65 - NCT07450144Recruiting
Chatbot to Help Reduce Alcohol in Fatty Liver Disease
This study tests a chatbot that helps people with fatty liver disease reduce how much they drink. If you drink regularly and are ready to change, this tool could support you.
Hong KongAges 18 years+ - NCT07440511Recruiting
Spleen stiffness test for advanced liver scarring
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
RomeAges 18 years+ - NCT07437157Recruiting
Hong Kong diabetes fatty liver disease study
This research study looks at people with type 2 diabetes to learn more about fatty liver disease. By joining, you may help doctors better understand how these conditions are linked and improve future care.
Hong Kong, New TerritoriesAges 18 years+ - NCT06813508Recruiting
Liver cancer and transplant study for MASLD patients
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
Bologna, BolognaAges 18 years+ - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT07412444Recruiting
Olive oil study for fatty liver health
This trial tests if extra virgin olive oil (EVOO) can improve liver health in people with metabolic fatty liver disease (MASLD). It may help reduce fat in the liver and improve overall metabolic health.
Castellana Grotte, ItalyAges 18–65 - NCT07400367Recruiting
Probiotics and lifestyle changes for fatty liver disease
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
New Taipei CityAges 18–80 - NCT07390422Recruiting
PulsENDO for diabetes and fatty liver
This trial tests a new endoscopic procedure (pulsENDO) for people with type 2 diabetes and fatty liver disease whose blood sugar remains high despite taking diabetes pills. It aims to see if this treatment can improve blood sugar control and liver health.
ShatinAges 18–70 - NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07378072Recruiting
12-week daytime eating study for fatty liver in obesity
This study tests if restricting eating to daytime hours for 12 weeks can reduce liver fat in people with obesity. It aims to help those with fatty liver disease improve their health without medication.
AngersAges 18–65 - NCT07335601RecruitingPhase 2
Resmetirom for liver health after transplant in MASH patients
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
La Jolla, CaliforniaAges 18–75 - NCT07325526RecruitingPhase 2
Testing an experimental drug for liver cirrhosis caused by MASH
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
Chandler, ArizonaAges 18–75 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT06867419Recruiting
Metabolic effects on fatty liver disease score
This study looks at how certain features of your metabolism affect a simple score (called the FAST score) in people with fatty liver disease (MASLD). It aims to help doctors better understand and manage the condition.
Tanta, GharbyeaAges 18 years+ - NCT07321925Recruiting
Using sound waves to measure liver fat
This study tests a new method that uses sound waves to measure fat in your liver. It could help doctors check liver health without a biopsy.
Ann Arbor, MichiganAges 18 years+
Hear when a new Metabolic Dysfunction-Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated liver disease?
- Yes. Clin2 currently lists 112 recruiting metabolic dysfunction-associated liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Fatty Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Liver Dysfunction
- Alcohol-associated Liver Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.